Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
doi: 10.1210/me.2006-0178 73 RoedSNNhrACWismannPIversenHBruner-OsborneHKnudsenSMet al
PlexusDx uses these 150+ insights to personalize your therapy approach
Markowitz et al, 1988
Yet while reducing cardiovascular disease by treating high cholesterol, high blood pressure, and diabetes is standard practice, the concept of treating obesity to reduce cardiovascular complications has been hampered by the lack of evidence that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes, said Michael Lincoff, M.D., SELECTs lead author and vice chair for research in Cleveland Clinics Department of Cardiovascular Medicine
Combination with Metformin or Metformin with Sulfonylurea In a 56-week, open-label trial (NCT01885208), 813 patients with type 2 diabetes mellitus on metformin alone (49%), metformin with sulfonylurea (45%), or other (6%) were randomized to semaglutide 1 mg once weekly or exenatide 2 mg once weekly
.jpg)
US$ 21.44
US$ 28.97
US$ 22.41
US$ 24.18
US$ 27.66
US$ 21.43
